Navigation Links
Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
Date:1/30/2008

SAN CARLOS, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it has enrolled the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172, a thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers.

"This proof-of-concept trial will allow us to quickly determine NU172's potential to achieve rapid onset and offset of anticoagulation," said Michael Levy, executive vice president of research and development for Nuvelo. "We look forward to sharing top-line data from this trial in the first half of 2008."

NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions. Data from early animal models suggest that NU172 has the potential for predictable anticoagulant effects, rapid onset and offset of action, and avoidance of heparin-induced thrombocytopenia.

About Aptamers

Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and affinity, and the ability to target protein-protein interactions.

About Nuvelo and Archemix's Joint Collaborative Effort

In August 2006, Nuvelo expanded its collaboration with Archemix to develop and commercialize aptamers that have a sho
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
4. Northwestern Memorial Transplant Program Initiates New Study
5. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
6. SGX Initiates Phase I Trials for SGX523
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
9. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
10. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
11. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... VIEW, Calif. , Oct. 30, 2014 /PRNewswire/ ... accelerated dramatically as a result of government initiatives ... time - healthcare providers have invested over the ... the heart of health IT, and U.S. clinicians ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... FRANCISCO , Oct. 30, 2014  Nektar Therapeutics ... results for the third quarter ended September 30, 2014 ... U.S.-based financial markets. Howard Robin , president and ... review the results beginning at 5:00 p.m. Eastern Time ... press release and a live audio-only Webcast of the ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... YORK, Sept. 9 New York Blood Center (NYBC), serving ... Island, the Hudson Valley and New Jersey, calls upon our ... and Labor Day holiday weekend have resulted in fewer donations ... B-negative blood for patients in need. Donations from ...
... Polycystic Ovarian Syndrome, known as PCOS, is a silent ... body and increases the risk of serious illness. ... and increases the risk of heart disease, insulin resistance, diabetes ... abnormality in women of child bearing age, affecting 5 to ...
Cached Medicine Technology:Blood Donors Needed as School, Fall Season Returns 2Blood Donors Needed as School, Fall Season Returns 3Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 2Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 3
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician ... practices; OB GYN in Melrose Park, IL and ... contains important information about each of the care services and ... forms in English and Spanish. The navigation of the ... the website provide Dr. Furlin’s patients with important information regarding ...
(Date:10/30/2014)... October 30, 2014 USARAD ... Accredited teleradiology and specialty telemedicine solutions provider, including ... to its existing teleradiology services at Mission Bend ... and expert telemedicine services, to the state-of-the-art, 24/7, ... a result of this innovative partnership, there will ...
(Date:10/30/2014)... The annual meeting of The ... close on Saturday, October 18th, marking the end of ... 1989. NAMS is North America’s leading non-profit organization dedicated ... all women during midlife and beyond through an understanding ... and thought leaders from fields as varied as gynecology, ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- When it comes to heart ... men to delay care when they have symptoms that spell ... to the hospital with a more severe or advanced stage ... study author Catherine Kreatsoulas, a Fulbright Scholar and research fellow ... news release from the Heart and Stroke Foundation of Canada. ...
(Date:10/30/2014)... By Dennis Thompson ... -- Drinking lots of milk could be bad for your ... that the calcium in milk can help strengthen bones and ... health officials to recommend milk as part of a healthy ... amounts of milk did not protect men or women from ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... have newly identified 34 unique variations in the human ... sclerosis (ALS). ,The 34 so-called single nucleotide ... to the non-inherited form of the fatal neurodegenerative disease. ... responsible for sporadic ALS, our results seriously narrow the ...
... arteries and giving blood at six-monthly intervals to promote iron reduction ... ,A normal adult has five to six litres of blood ... blood donation. This blood is replaced by the body within 24 ... VA Medical Centre and the Dartmouth Medical School in Vermont looked ...
... for primary ciliary dyskinesia, a rare genetic disease that ... ,According to Thomas Ferkol, M.D., Washington University School of ... of patients with primary ciliary dyskinesia (PCD) have a ... of PCD requires a high index of suspicion, but ...
... such as Tenormin, Inderal and Lopressor should not be a ... a large new review of studies. ,The review, ... that beta-blocker users have a slightly higher risk of death ... such as Norvasc and Cardizem to manage their blood pressure. ...
... determined that low levels of a protein in the blood ... artery disease. ,In a group of men ... Activation, Normal T-cell Expressed, and Secreted), also known as CCL5, ... ,RANTES is a chemokine produced by a variety ...
... breast cancer prevention among women at high risk of the ... found that the breast cancer risk reduction persists long after ... to treat breast cancer and to prevent it among women ... data on tamoxifen for breast cancer prevention comes from the ...
Cached Medicine News:Health News:Human Genetic Code for ALS Identified 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3Health News:Beta-Blockers Should Not Be First Choice for High Blood Pressure 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: